25 July 2017 **Sydney, Australia**

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:
Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operations Office:
Suite 3 Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

NOXOPHARM POSTS NEW CORPORATE PRESENTATION

- **Singapore, Hong Kong roadshow**
- **July 26-28, 2017**

Sydney, 25 July 2017: Noxopharm Limited (ASX: NOX) provides its latest Corporate Presentation ahead of a roadshow (26-28) in Asia.

For further information, please contact:

Investor & Corporate Enquiries:

Prue Kelly

M: 0459 022 445
info@noxopharm.com

Company Secretary :

David Franks

T: +61 2 9299 9690
E: dfranks@fa.com.au

www.noxopharm.com

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney, Melbourne and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of resistance in cancer cells to radiotherapy and chemotherapy, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates including idronoxil-C under development. The Company also has an expanding pipeline of non-oncology drugs.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances

and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

NOXOPHARM

Corporate Presentation

July 2017

ASX: NOX

After 50 years ……..

- despite all the advances in medical technology
- and despite all the ‘breakthroughs’ in cancer therapy

standard chemotherapy and radiotherapy remain the **front-line, ‘go to’ therapies for most cancers**

Non-specific ‘poisons’ …….

- cytotoxic chemotherapy
- radiotherapy

….. remain the best treatment options we have

But clearly are not good enough …



Source; Cancer Research UK

After 45 years 10-year survival rates remain poor for many common cancers

A problem only getting worse with an increasingly ageing society



NOXOPHARM

Over the last 5 years

- New breakthroughs in cancer treatment
- Focused on “immuno-oncology”

→ using the body’s immune system to help fight cancer



(Source: https://www.opdivo.com/advanced-nsclc/about-opdivo/clinical-trial-results)

Positive news for some patients, however…



… a very long way to go

- Improves the 50% survival rate from 9.4 months to 12.4 months
- Shrinks tumours in 19% of patients, up from 12%
- No difference in overall time to worsening of cancer

(Source: https://www.opdivo.com/advanced-nsclc/about-opdivo/clinical-trial-results)

Our aim …

To bring to market a drug that

- boosts the potency of chemotherapy and radiotherapy
- without increasing their toxicity

and becomes a standard-of-care drug in oncology

That drug is …

NOXOPHARM

NOX66

With a target of reaching market by 2022

NOX66

Aiming to be used with both chemotherapy and radiotherapy

But… **focusing on radiotherapy, potentially the more curative of the two**

Aiming to be used for most forms of cancer

But… **focusing on prostate, lung and brain cancers**

- **Radiotherapy** generally considered to be the **most effective** form of anti-cancer therapy
- But …toxicity limits dosage = limited response rates
- *Research effort over many years to develop means of making cancer cells more sensitive to radiotherapy*

- No radio-sensitising drug has yet come to market that makes radiotherapy more effective in a safe way
- Such a drug should command a premium price and place in cancer therapy
- *NOXOPHARM believes that NOX66 is that drug and is seeking to have it commercially available by 2022*

How radiotherapy works

DNA damaged



Repair pathway

Sphingosine-1-phosphate

Akt/PI3 kinase

- PARP1
- Topoisomerase 1 and 2



Damage repaired over 7 days

Aim of radiotherapy is to inflict so much DNA damage that it cannot be repaired
➡ cell death

Problem: cancer cells greatly increase DNA repair capacity making radiation less effective.

Dose of radiotherapy required to kill all cancer cells too toxic.

How NOX66 works

DNA damaged



Repair pathway

- Sphingosine-1-phosphate
- ATR/ATM kinase
- PARP
- Topoisomerase 1 and 2

Damage repaired over 7 days



NOX66 blocks DNA repair mechanisms in cancer cells only.

Cancer cells unable to repair even minor damage.

Converts non-lethal damage into lethal damage at a safe dose of radiotherapy

NOX66… why it works



Idronoxil

LIPROSE
(Lipid Protective Shield)

NOX66

- High levels of active drug in body
- Slowly excreted (> 12 hours)
- Crosses blood-brain barrier (pre-clinical)

Radiotherapy… *unable to treat metastatic disease*

Prostate cancer viewed by standard scan (CT, MRI, bone scan)



Prostate cancer viewed by radioactive antibody scan

Radio-sensitising responses with NOX66

1. Direct
2. Indirect (abscopal)

NOXOPHARM



Palliative external radiotherapy

+ NOX66



Direct radio-sensitising effect

+ NOX66



Abscopal effect

Prostate and lung cancer studies
1º strategy: abscopal effect

- Metastatic cancer (at least 3 lesions)
- 1-2 largest lesions irradiated
- Palliative (low) dose of radiation
- NOX66 daily for duration of radiation + 7 days
- Measure response of irradiated lesions
- Measure response of non-irradiated lesions



Prostate and lung cancer studies.
2º strategy: direct radio-sensitisation, but no abscopal effect

- Metastatic cancer (at least 3 lesions)
- 1-2 largest lesions irradiated
- Palliative (low) dose of radiation + NOX66 + chemotherapy
- Measure response of irradiated lesions
- Measure response of non-irradiated lesions



Prostate cancer studies.

3º strategy: direct radio-sensitisation of all cancerous lesions

NOXOPHARM

Radioactive antibody





^{177} Lutetium-PSMA

NOX66 clinical program

Chemo alone	**4x sites: Georgia**	**Lung, breast, ovary, prostate, head & neck**
External radiation	**Multiple sites : Aust**	**Prostate**
External radiation	**Single site : Aust**	**Prostate**
Brachytherapy	**Single site : Australia**	**Prostate**
External radiation	**Multiple sites : Aust/HK**	**Lung**
External radiation + chemo	**Multiple sites : Aust/NZ**	**Lung, prostate**

NOX66 clinical program

Chemo alone	4x sites: Georgia
External radiation	Multiple sites : Aust
External radiation	Single site : Aust
Brachytherapy	Single site : Aust
External radiation	Multiple sites : Aust/HK
External radiation + chemo	Multiple sites : Aust/NZ



Planning for success: registration studies late-2018



Preparation for success:

GMP Manufacture

- Idronoxil *(Contract)*
- NOX66 *(Self)*
- Idronoxil-C *(Self)*

Regulatory Affairs

- NOX66 *(Registration studies/licensing)*
- IND/Orphan Drug applications

Clinical Trials/Medical Affairs

- Planning
- Oversight
- Data Management
- Conference data

Pre-Clinical

- Basic science
- IND studies

NOX66: **potential to treat brain cancer**



Previous dosage forms of idronoxil did **not** deliver drug into brain

NOX66 **does** deliver idronoxil into brain

Aim is to use NOX66 to sensitise brain cancers to low doses of radiotherapy

NOX66: brain cancer program

Adult Primary: glioblastoma



Adult Secondary: lung, breast, melanoma



Paediatric Primary: DIPG

Key Messages

- WE EXPECT TO KNOW BY END OF 2017 OF THE SUCCESS OF OUR MISSION
- WE AIM TO BE IN A REGISTRATION STUDY BY END OF 2018
- WE AIM TO HAVE MARKETING APPROVAL BY 2022
- A SUCCESSFUL OUTCOME IS A MAJOR SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET
- REALISTIC POTENTIAL TO COME STANDARD OF CARE DRUG IN MOST CANCER PATIENTS

✓ Lean operation ✓ Experienced team	✓ key inflection points anticipated within next 6-12 months	✓ Several potential blockbuster drugs candidates

Key metrics

Shares outstanding	**85M** : 38M free; 47M escrowed (July 2018)
Other	22.5M options ($0.30) (2018)
Market Cap (29.7.2017)	$27M
Cash position	AU$ 6.0M IPO (9 Aug 2016) AU$ 2.8M (Jun 2017)

Disclaimer

- *This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.*
- *This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.*
- *This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.*
- *Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.*
- *Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.*

NOXOPHARM

NOXOPHARM

Dr Graham Kelly
Chief Executive Officer

graham.kelly@noxopharm.com